CIT GAP Funds Invests in STR, LLC
Joseph W. Reilly, Chief Executive Officer of STR, said, "CIT's investment and counsel will help us begin developing the animal study protocol that will help the company reach the next stage of its development."
STR, LLC, develops breakthrough technology for soft tissue regeneration of the anterior cruciate ligament ("ACL") of the knee. The company plans to introduce its product, called the L-C Ligament(TM), to a market that averages 300,000 ACL reconstructions per year in the US, EU, Canada, Japan and Australia. The current standard of care -- primarily consisting of autografts and allografts -- have significant issues, which the L-C Ligament(TM) intends to address by stabilizing the knee and encouraging the regeneration of ligament tissue, resulting in faster, better healing and greater odds of making a full recovery.
"We agree with STR that there is a great need for a synthetic ACL, considering the many problems with the current standard of care," Peter Jobse, CIT president and CEO said. "As our population increases with more aging, active adults, that need will only expand and the marketplace will be ripe for this and other innovative medical breakthroughs."
CIT GAP Funds is a family of venture funds designed to bridge the gap between "family and friends" funding and early-stage equity investments for Virginia-based technology and life science companies. CIT GAP Funds invests in seed-stage firms with a high potential for successful commercialization, rapid growth and downstream private equity financing.
"STR is CIT GAP Funds' twenty-fifth investment," noted Tom Weithman, CIT GAP Funds managing director. "Those investments have leveraged over another $21 million of private equity investments in emerging Virginia companies, which moves innovation into the marketplace faster."
Summaries of the CIT GAP Funds portfolio companies are available at http://www.citgapfund.org/portfolio/gapfundi.html.
About the Center for Innovative Technology, www.cit.org
CIT is a nonprofit corporation that accelerates the next generation of technology and technology companies. CIT creates new technology companies through capital formation, market development and revenue generation services. To facilitate national innovation leadership and accelerate the rate of technology adoption, CIT creates partnerships between innovative technology start-up companies and advanced technology consumers. CIT is now listed on the GSA MOBIS Schedule, Special Item Numbers (SINs) SIN 874-1 for Consulting Services and SIN 894-2 for Facilitation Services. Its CAGE Code is 1UP71.
SOURCE Center for Innovative Technology
You May Also Like